146 related articles for article (PubMed ID: 37870712)
1. Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis.
Viscovo M; Metafuni E; Giammarco S; Santopaolo F; Frioni F; Pellegrino C; Sica S; Chiusolo P; Pompili M
Eur J Clin Microbiol Infect Dis; 2023 Dec; 42(12):1543-1545. PubMed ID: 37870712
[No Abstract] [Full Text] [Related]
2. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
[TBL] [Abstract][Full Text] [Related]
5. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
6. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
Knöll A; Boehm S; Hahn J; Holler E; Jilg W
J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
[TBL] [Abstract][Full Text] [Related]
7. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Wu Y; Huang H; Luo Y
Front Immunol; 2020; 11():610500. PubMed ID: 33613534
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience.
Faraci M; Cappelli B; Lanino E; Morreale G; Fioredda F; Giudice CL; Giacchino R
Pediatr Transplant; 2009 Nov; 13(7):923-6. PubMed ID: 19032422
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
[TBL] [Abstract][Full Text] [Related]
10. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.
Idilman R; Arat M
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):641-52. PubMed ID: 21819330
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
13. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
[TBL] [Abstract][Full Text] [Related]
14. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
Milazzo L; Corbellino M; Foschi A; Micheli V; Dodero A; Mazzocchi A; Montefusco V; Zehender G; Antinori S
Transpl Infect Dis; 2012 Feb; 14(1):95-8. PubMed ID: 21749588
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.
Gupta A; Punatar S; Gawande J; Bagal B; Mathew L; Bhat V; Kannan S; Khattry N
Hematol Oncol; 2016 Sep; 34(3):140-6. PubMed ID: 25690950
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation.
Zhang JW; Zhang XZ; Sun YL; Long B; Wang XZ; Li XD
BMC Infect Dis; 2019 Jan; 19(1):57. PubMed ID: 30651070
[TBL] [Abstract][Full Text] [Related]
19. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation.
Henkes M; Martin S; Einsele H; Aulitzky WE
Ann Hematol; 2002 Jun; 81(6):343-6. PubMed ID: 12107567
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients.
Moses SE; Lim Z; Zuckerman MA
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):891-9. PubMed ID: 21973301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
